Merck Agrees to Acquire Bio-Techne, Strengthening Leadership Position in Fast-Growing Life Sciences Markets

Merck to Acquire Bio-Techne, Expanding Leadership in High-Growth Life Sciences Markets

Merck Agrees to Acquire Bio-Techne, Strengthening Leadership Position in Fast-Growing Life Sciences Markets Merck, a leading science and technology company, and Bio-Techne Corporation, a Minneapolis-based global provider of life science tools, analytical technologies, and consumables, today entered into a definitive…

Read MoreMerck to Acquire Bio-Techne, Expanding Leadership in High-Growth Life Sciences Markets
Antares Therapeutics

Antares Therapeutics Partners with Novartis to Discover, Develop, and Commercialize First-in-Class Cancer Therapies

Antares Therapeutics Enters Agreement with Novartis to Discover, Develop and Commercialize First-in-Class Cancer Therapies Antares Therapeutics, Inc. a biotechnology company developing first-in-class precision medicines for cancer and other serious diseases, today announced a strategic collaboration with Novartis to discover, develop…

Read MoreAntares Therapeutics Partners with Novartis to Discover, Develop, and Commercialize First-in-Class Cancer Therapies
Verici

Verici Dx Receives New York State Approval, Expanding Nationwide Access to the Tutivia™ Kidney Transplant Rejection Test

Verici Dx Receives New York State Approval, Establishing Nationwide Access to Tutivia™ Kidney Transplant Rejection Test Verici Dx plc  a developer of advanced clinical diagnostics for organ transplant, announced it has received clinical laboratory accreditation from the New York State…

Read MoreVerici Dx Receives New York State Approval, Expanding Nationwide Access to the Tutivia™ Kidney Transplant Rejection Test
Definium Therapeutics

Definium Therapeutics Reports Positive Phase 3 Results for DT120 ODT in Major Depressive Disorder

Definium Therapeutics Announces Positive Topline Results from Phase 3 Emerge Study of DT120 Orally Disintegrating Tablet (ODT) in Major Depressive Disorder Definium Therapeutics, Inc. a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes…

Read MoreDefinium Therapeutics Reports Positive Phase 3 Results for DT120 ODT in Major Depressive Disorder
Pheno Therapeutics

Pheno Therapeutics Receives FDA IND Clearance for Lead Multiple Sclerosis Candidate PTD802

Pheno Therapeutics Granted FDA IND Clearance for Lead Multiple Sclerosis Therapeutic Candidate PTD802 Pheno Therapeutics Limited. (Pheno), a clinical stage biotechnology company focused on the discovery and development of small molecule therapeutics for the treatment of neurological diseases, today announced…

Read MorePheno Therapeutics Receives FDA IND Clearance for Lead Multiple Sclerosis Candidate PTD802
Bionyra Pharma

Bionyra Pharma Launches with Oversubscribed $165 Million Series A to Advance Next-Generation Biologics

Bionyra Pharma Launches with $165 million Oversubscribed Series A to Advance Clinical Stage Pipeline of Next Generation Biologics for Immune-Mediated Inflammatory Diseases Bionyra Pharma, a clinical-stage biopharmaceutical company developing next-generation biologics for immune-mediated inflammatory diseases, today announced the company’s launch…

Read MoreBionyra Pharma Launches with Oversubscribed $165 Million Series A to Advance Next-Generation Biologics
Greenstone Biosciences, Inc. and Intel Corp. Launch Strategic Collaboration to Scale Human-Centric Drug Discovery

Greenstone Biosciences and Intel Partner to Advance Human-Centric Drug Discovery at Scale

Greenstone Biosciences, Inc. and Intel Corp. Launch Strategic Collaboration to Scale Human-Centric Drug Discovery Greenstone Biosciences, Inc. announces a collaboration with Intel Corp. to accelerate AI-enabled drug discovery using Greenstone’s large-scale, human biobank of induced pluripotent stem cells and Intel’s Edge AI advanced computing and AI infrastructure. Intel and Greenstone are working together…

Read MoreGreenstone Biosciences and Intel Partner to Advance Human-Centric Drug Discovery at Scale
Haypp

Haypp Group Critique Challenges Seizure Claims Linked to Nicotine Pouches in Animal Study

New Critique by Haypp Group Warns Seizure Claims About Nicotine Pouches Overstate Animal Study Findings Giving mice a chemically induced epileptic condition and then adding nicotine does not prove that nicotine causes or worsens seizures, according to Haypp Group’srecently published…

Read MoreHaypp Group Critique Challenges Seizure Claims Linked to Nicotine Pouches in Animal Study